HSV Based Virotherapy Market Size

  • Report ID: 3115
  • Published Date: Dec 24, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2025-2037

Herpes Simplex Virus Treatment Market size was valued at USD 2.84 billion in 2024 and is expected to reach USD 7.45 billion by 2037, expanding at around 7.7% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of herpes simplex virus treatment is assessed at USD 3.03 billion.
 

The growth of the market can be attributed to the growing prevalence of rare kinds of cancer, and the growing demand for better and more effective treatments for cancer. According to the data by the World Health Organization (WHO), cancer is the second leading cause of death and caused over 10 million deaths in 2020. The virotherapy is a new approach for treatment of various diseases which do not have any existing cures. In Herpes simplex virus treatment, herpes simplex virus is mutated in a controlled environment and is used to destroy the cancerous cells in the patient’s body. Moreover, increasing research and development in medical science, along with mounting investment by major pharmaceutical companies to develop new treatment approach, is estimated to boost the market growth.


Global-HSV-Based-Virotherapy-Market-Overview

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of herpes simplex virus treatment is assessed at USD 3.03 billion.

Herpes Simplex Virus Treatment Market size was valued at USD 2.84 billion in 2024 and is expected to reach USD 7.45 billion by 2037, expanding at around 7.7% CAGR during the forecast period i.e., between 2025-2037.

North America industry is predicted to account for largest revenue share by 2037, on the back of high government investment in this sector, along with presence of leading pharmaceutical companies conducting innovative clinical experiments.

The major players in the market are Sorrento Therapeutics, Inc., Replimune Group Inc., Shanghai Sunway Biotech Co., Ltd, Merck & Co, Inc., Amgen Inc., Oncolytics Biotech Inc., Transgene SA, PSIOXUS Therapeutics Limited and others.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos